What is Zacks Research's Estimate for AbbVie Q2 Earnings?

Key Points

• Zacks Research has raised its Q2 2027 EPS estimate for AbbVie to $3.85, slightly above the prior estimate of $3.84, while the company’s full-year earnings consensus stands at $12.31 per share.
• AbbVie recently reported quarterly earnings of $2.97 per share, missing the analysts' consensus estimate by ($0.27), but generated revenues of $15.42 billion, exceeding expectations.
• The company declared a quarterly dividend of $1.64 per share, representing an annualized dividend yield of 3.0%, with a reported dividend payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Zacks Research upped their Q2 2027 EPS estimates for shares of AbbVie in a report released on Thursday, September 18th. Zacks Research analyst Team now expects that the company will earn $3.85 per share for the quarter, up from their previous estimate of $3.84. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie's FY2027 earnings at $15.25 EPS.

Other equities research analysts have also recently issued research reports about the stock. Berenberg Bank raised shares of AbbVie from a "hold" rating to a "buy" rating and increased their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Wells Fargo & Company raised their price target on shares of AbbVie from $240.00 to $260.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Citigroup increased their price objective on shares of AbbVie to $205.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Daiwa America raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 7th. Finally, Evercore ISI lifted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an "outperform" rating in a research note on Monday. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $223.45.

AbbVie Stock Up 0.8%

NYSE:ABBV traded up $1.82 during midday trading on Friday, reaching $224.29. 2,391,736 shares of the stock traded hands, compared to its average volume of 6,459,258. AbbVie has a 12-month low of $163.81 and a 12-month high of $225.16. The business has a 50-day moving average of $203.12 and a two-hundred day moving average of $194.78. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a market capitalization of $396.22 billion, a PE ratio of 106.78, a price-to-earnings-growth ratio of 1.33 and a beta of 0.53.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.65 earnings per share.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 2.9%. AbbVie's dividend payout ratio is 312.38%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the company's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. This represents a 18.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company's stock.

Hedge Funds Weigh In On AbbVie

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Hawaiian Bank increased its stake in AbbVie by 0.8% in the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock worth $1,403,000 after purchasing an additional 60 shares in the last quarter. Narus Financial Partners LLC grew its stake in AbbVie by 25.3% during the 1st quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock valued at $417,000 after acquiring an additional 401 shares in the last quarter. Highland Capital Management LLC grew its stake in shares of AbbVie by 6.3% in the 1st quarter. Highland Capital Management LLC now owns 46,853 shares of the company's stock valued at $9,817,000 after buying an additional 2,792 shares in the last quarter. Weaver Capital Management LLC grew its stake in shares of AbbVie by 3.9% in the 1st quarter. Weaver Capital Management LLC now owns 8,240 shares of the company's stock valued at $1,727,000 after buying an additional 310 shares in the last quarter. Finally, North Star Asset Management Inc. grew its stake in shares of AbbVie by 0.5% in the 1st quarter. North Star Asset Management Inc. now owns 161,320 shares of the company's stock valued at $33,800,000 after buying an additional 756 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.